United Therapeutics Corporation (NASDAQ:UTHR) Receives $533.55 Consensus Price Target from Analysts

United Therapeutics Corporation (NASDAQ:UTHR) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $533.5455.

Several brokerages recently issued reports on UTHR. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Oppenheimer raised their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday. Finally, Wells Fargo & Company upped their price objective on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th.

United Therapeutics Stock Down 1.7%

Shares of NASDAQ:UTHR opened at $490.21 on Friday. The company has a market capitalization of $21.48 billion, a price-to-earnings ratio of 17.57, a price-to-earnings-growth ratio of 1.79 and a beta of 0.84. The firm has a 50 day moving average of $483.67 and a 200 day moving average of $450.90. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $537.19.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same period last year, the business earned $6.19 EPS. The company’s revenue was up 7.4% compared to the same quarter last year. On average, sell-side analysts expect that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity

In other news, CFO James Edgemond sold 21,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at approximately $3,896,761.20. This trade represents a 72.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $496.30, for a total transaction of $11,166,750.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 356,454 shares of company stock worth $172,894,963. 10.30% of the stock is owned by corporate insiders.

Institutional Trading of United Therapeutics

Large investors have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management grew its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC increased its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new position in United Therapeutics in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.